CDK1 and breast carcinoma: Silencing eIF3d in renal cell carcinoma is known to down-regulate the cell cycle B1/cyclin-dependent kinase-1 (CDK1) signalling pathway [36], and knocking down eIF3d in breast cancer cells inhibits the Wnt/β-catenin signalling pathway [33].